Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIRCLE phase 2 trial of ocriplasmin for inducing total posterior vitreous detachment in non-proliferative diabetic retinopathy
2015-002415-15Phase 2Terminated
- Sponsor
- Oxurion
- Start
- Nov 2015
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ocriplasmin in nonproliferative diabetic retinopathy (NPDR) (3 arms), sponsored by Oxurion. Primary endpoint: Total posterior vitreous detachment by Month 3. Started Nov 2015; status: terminated.
02
Drugs
ocriplasmin
03
Conditions
nonproliferative diabetic retinopathy (NPDR)
Beyond the preview
Go deeper on 2015-002415-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002415-15.